SageView Advisory Group LLC Acquires Shares of 7,465 Qiagen (NYSE:QGEN)

SageView Advisory Group LLC bought a new position in shares of Qiagen (NYSE:QGEN) during the fourth quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The institutional investor bought 7,465 shares of the company’s stock, valued at approximately $325,000.

Several other hedge funds also recently made changes to their positions in the business. Wellington Management Group LLP grew its position in Qiagen by 20.1% during the fourth quarter. Wellington Management Group LLP now owns 7,271,828 shares of the company’s stock worth $316,463,000 after buying an additional 1,217,712 shares in the last quarter. Quarry LP acquired a new stake in shares of Qiagen during the 4th quarter worth $38,000. FIL Ltd increased its position in shares of Qiagen by 8.5% in the fourth quarter. FIL Ltd now owns 5,099,140 shares of the company’s stock worth $221,784,000 after purchasing an additional 399,965 shares during the period. DZ BANK AG Deutsche Zentral Genossenschafts Bank Frankfurt am Main raised its stake in Qiagen by 0.8% in the fourth quarter. DZ BANK AG Deutsche Zentral Genossenschafts Bank Frankfurt am Main now owns 3,481,873 shares of the company’s stock valued at $151,526,000 after purchasing an additional 26,078 shares in the last quarter. Finally, Parkman Healthcare Partners LLC bought a new stake in Qiagen during the fourth quarter worth about $10,858,000. 70.00% of the stock is owned by institutional investors.

Qiagen Stock Up 0.0 %

Shares of NYSE:QGEN opened at $43.75 on Thursday. The company has a debt-to-equity ratio of 0.25, a quick ratio of 1.45 and a current ratio of 1.84. Qiagen has a 52-week low of $34.74 and a 52-week high of $47.70. The company has a market capitalization of $9.98 billion, a PE ratio of 29.34, a price-to-earnings-growth ratio of 3.61 and a beta of 0.42. The company has a fifty day moving average of $43.01 and a 200-day moving average of $43.65.

Qiagen (NYSE:QGEN) last posted its earnings results on Monday, April 29th. The company reported $0.46 EPS for the quarter, beating the consensus estimate of $0.44 by $0.02. The firm had revenue of $459.00 million during the quarter, compared to the consensus estimate of $453.91 million. Qiagen had a return on equity of 12.59% and a net margin of 17.38%. The business’s quarterly revenue was down 5.4% on a year-over-year basis. During the same period last year, the company earned $0.53 earnings per share. On average, equities analysts predict that Qiagen will post 2.14 EPS for the current fiscal year.

Analyst Upgrades and Downgrades

Several equities analysts have recently commented on QGEN shares. JPMorgan Chase & Co. boosted their target price on shares of Qiagen from $52.00 to $54.00 and gave the company an “overweight” rating in a research report on Tuesday. Stifel Nicolaus cut their target price on Qiagen from $55.00 to $45.00 and set a “hold” rating for the company in a research note on Wednesday, May 1st. Four equities research analysts have rated the stock with a hold rating and six have issued a buy rating to the company’s stock. According to data from MarketBeat, the stock has an average rating of “Moderate Buy” and a consensus price target of $51.17.

Qiagen Company Profile

QIAGEN N.V. offers sample to insight solutions that transform biological materials into molecular insights worldwide. The company provides primary sample technology consumables, such as nucleic stabilization and purification kits for primary sample materials, manual and automated processing for genotyping, gene expression, and viral and bacterial analysis, as well as silica membranes and magnetic bead technologies; secondary sample technology consumables, including kits and components for purification of nucleic acids from secondary sample materials; and instruments for nucleic acid purification and accessories.